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Abstract
Background: Recent studies have suggested that the Src inhibitor dasatinib preferentially inhibits the growth of
breast cancer cells of the basal-like subtype. To clarify this finding and further investigate combined antitumor
effects of dasatinib with cytotoxic agents, a panel of breast cancer cell lines of various subtypes was treated with
dasatinib and/or chemotherapeutic agents.
Methods: Seven human breast cancer cell lines were treated with dasatinib and/or seven chemotherapeutic
agents. Effects of the treatments on c-Src activation, cell growth, cell cycle, apoptosis and the proportion of
aldehyde dehydrogenase (ALDH) 1-positive cells were examined.
Results: The 50%-growth inhibitory concentrations (IC50s) of dasatinib were much lower in two basal B cell lines
than those in the other cell lines. The IC50s of chemotherapeutic agents were not substantially different among the
cell lines. Dasatinib enhanced antitumor activity of etoposide in the basal B cell lines. Dasatinib induced a G1-S
blockade with a slight apoptosis, and a combined treatment of dasatinib with etoposide also induced a G1-S
blockade in the basal B cell lines. Dasatinib decreased the expression levels of phosphorylated Src in all cell lines.
Interestingly, dasatinib significantly decreased the proportion of ALDH1-positive cells in the basal B cell lines but
not in the other cell lines.
Conclusions: The present study indicates that dasatinib preferentially inhibits the growth of breast cancer cells of
the basal B subtype associated with a significant loss of putative cancer stem cell population. A combined use of
dasatinib with etoposide additively inhibits their growth. Further studies targeting breast cancers of the basal B
subtype using dasatinib with cytotoxic agents are warranted.
Background
Gene expression microarray analyses have revealed that
breast cancers consist of several distinctive subtypes
[1,2]. Most breast cancers classified into the basal-like
subtype have an estrogen receptor (ER)-negative, pro-
gesterone receptor (PgR)-negative and human epidermal
growth factor receptor (HER) 2-negative (so-called “tri-
ple-negative”) phenotype [3]. Because of the lack of
molecular targets in triple-negative/basal-like breast
cancers and their aggressive biological behaviors, novel
treatment strategies against them have been intensively
investigated [4].
Recent preclinical studies have shown that a multiple
tyrosine kinase inhibitor, dasatinib, has a more potent
antitumor effect on triple negative/basal-like breast can-
cer cells than those of other subtypes [5,6]. It is sug-
gested that one of the targets of dasatinib, the Src
tyrosine kinase pathway, is responsible for its antitumor
activity. Otherwise, several molecular markers for pre-
dicting the antitumor activity of dasatinib have been
already reported [6]. * Correspondence: kure@med.kawasaki-m.ac.jp
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cated that most triple negative/basal-like breast cancers
have dysfunctional BRCA1 or loss of BRCA1 expression
[7-9]. BRCA1 plays important roles in maintenance of
genetic stability including DNA double-strand break
repair [10]. Preclinical and clinical studies have suggested
that triple negative/basal-like breast cancers are sensitive
to DNA-damaging agents such as cisplatin (Cis) [10,11].
To clarify preferential antitumor activity of dasatinib
and DNA-damaging agents in triple negative/basal-like
breast cancer cells, we investigated antitumor effects of
dasatinib and various chemotherapeutic agents including
DNA-damaging agents on a panel of breast cancer cell
lines of various subtypes. In addition, in consideration
of future clinical implications, combined antitumor
activity of dasatinib with cytotoxic agents was also inves-
tigated. Furthermore, because recent translational stu-
dies have suggested that molecular targeting agents such
as trastuzumab and lapatinib may effectively decrease
the proportion of breast cancer stem cells associated
with a significant inhibition of non-stem cell growth,
changes in the proportion of aldehyde dehydrogenase
(ALDH) 1-positive cells, which may represent cancer
stem cells, were also examined [12-14].
Methods
Reagents
Dasatinib was provided by Bristol-Myers Squibb Phar-
maceutical Research Institute (Princeton, NJ). Etoposide
(Eto), doxorubicin (Dox), 5-fluorouracil (FU), paclitaxel
(Pac), Cis and carboplatin (Carb) were purchased from
Sigma Co. (St Louis, MI). An active metabolite of irino-
tecan hydrochloride, SN38 was provided by Dai-ichi
Sankyo Pharmaceutical Co. (Tokyo, Japan).
Breast cancer cell Lines and culture conditions
The KPL-1, KPL-3C and KPL-4 breast cancer cell lines
were established in our laboratory [15-17]. The MDA-
MB-231 cell line was provided by late Dr. Robert B.
Dickson (Lombardi Cancer Research Center, George-
town University Medical Center, Washington DC). The
MDA-MB-157, BT-474 and HCC-1937 cell lines were
obtained from the American Type Culture Collection
(Rockville, MD). All cell lines were routinely maintained
in Dulbecco’s modified Eagle’sm e d i u m( D - M E M )s u p -
plemented with 10% fetal bovine serum (FBS).
Cell growth analysis
To investigate the effects of dasatinib and/or che-
motherapeutic agents on cell growth, breast cancer cells
(1-5 × 10
4 cells per well) were seeded in 24-well plates
(SB Medical, Tokyo, Japan) and grown in D-MEM
supplemented with 10% FBS at 37°C in a 5% CO2 atmo-
sphere for two days. After washing with phosphate-
buffered saline (PBS), the cells were incubated with D-
MEM supplemented with 10% FBS plus indicated con-
centrations of dasatinib and/or chemotherapeutic agents
for three days. In the combination treatment, the cells
were incubated with D-MEM supplemented with 10%
FBS plus 0.1 μM dasatinib and the indicated concentra-
tions of the respective chemotherapeutic agents for
three days. After the incubation, the cells were harvested
and counted with a Coulter counter (Coulter Electro-
nics, Harpenden, UK). Reproducibility was confirmed in
at least two separate experiments.
To evaluate the antitumor effects of combined treat-
ments, a combination index based on 50% inhibitory
concentration (IC50) was calculated according to the fol-
lowing formula: combination index = IC50 with com-
bined treatment/IC50 with single treatment.
Combination index < 0.5 was considered evidence of
additive interaction [18].
Cell cycle and apoptosis analyses
To investigate the effect of agents on cell cycle progres-
sion, harvested cells were stained with propidium iodide
using a CycleTest Plus DNA Reagent kit (Becton Dick-
inson, San Jose, CA). Flow cytometry was performed
with a FACSCalibur flow cytometer (Becton Dickinson),
and the DNA histogram was analyzed using CELLQuest
version 1.2.2 (Becton Dickinson).
To investigate the effect of agents on apoptosis,
approximately 5 × 10
5 cells per well were plated into T-
25 flasks (Corning Japan, Tokyo, Japan) and cultured in
D-MEM supplemented with 10% FBS for two days. The
cells were then washed twice with PBS and cultured for
two days in D-MEM supplemented with 10% FBS plus
the indicated concentrations of dasatinib and/or che-
motherapeutic agents. Duplicate flasks were trypsinized
and harvested. The percentages of apoptotic cells were
measured by FACSCalibur flow cytometry (Becton Dick-
inson) using an Annexin-V-FLUOS staining kit (Roche
Diagnostics GmbH, Penzberg, Germany) according to
the manufacturer’s recommendations.
Immunocytochemistry
Harvested cells were washed once with cold PBS and
centrifuged at room temperature. The cell pellet was
fixed with 10% phosphate-buffered formalin overnight
and embedded in paraffin. The 5 μm paraffin sections
were dewaxed with xylene, hydrated with PBS, treated
with hydrogen peroxide and processed following an
immunoperoxidase procedure. The primary antibodies
used were: ER-a (1D5, monoclonal, 1:400, IMMUNO-
TECH, Marseilles, France), PgR (PgR636, monoclonal,
1:2,000, DAKO, Copenhagen, Denmark), HER2 (Her-
cepTest II, DAKO), HER1 (2-18C9, monoclonal,
DAKO), cytokeratin 5/6 (D5/16B4, monoclonal, 1:100,
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p53 (DO-7, monoclonal, 1:100, Nichirei Bioscience,
Tokyo, Japan), vimentin (V9, monoclonal, 1:100,
DAKO), c-Src (Src antibody, polyclonal, 1:800, Cell Sig-
naling Technology, Danvers, MA), p-SrcY416 (phos-
phor-Src family Tyr416 antibody, polyclonal, 1:100; Cell
Signaling Technology), p-Src Y527 (phosphor-Src family
Tyr527 antibody; polyclonal, 1:50; Cell Signaling Tech-
nology), and ALDH1 (monoclonal, IG isotype, 1:100; BD
Biosciences, San Jose, CA). After incubation, the slides
were washed in PBS or Tris-buffered saline for 15 min,
and each secondary antibody (mouse or rabbit) was
applied, using the LSAB kit (DAKO) or using the EnVi-
sion kit (DAKO). After washing, the color was devel-
oped with 5-bromo-4-chloro-3-indoxyl phosphate and
nitroblue tetrazolium chloride (DAKO). The slides were
then washed in distilled water for 5 min and mounted.
Control experiments were performed by substituting
normal rabbit or mouse serum for the first antibody.
Aldefluor assay
The ALDEFLUOR kit (StemCell Technologies, Durham,
NC) was used to isolate the population with a high
ALDH enzymatic activity. Harvested cells were sus-
pended in the ALDFLUOR assay buffer containing
ALDH substrate (BAAA, 1 μmol/l per 1 × 10
6 cells) and
incubated for 40 minutes at room temperature. As nega-
tive control, cells were treated with 50-mmol/l diethyla-
minobenzaldehyde (DEAB), a specific ALDH inhibitor.
Statistical analysis
All values are expressed as the mean ± SE. ANOVA
analysis with StatView computer software (ATMS Co.,
Tokyo, Japan) was used to compare the differences
between two groups. A two-sided P value less than 0.05
was considered statistically significant.
Results
Characteristics of breast cancer cell lines
To examine biological characteristics of a panel of breast
cancer cell lines, immunocytochemical analyses for ER-a,
PgR, HER2, HER1, cytokeratin 5/6, vimentin, BRCA1, p53,
c-Src, p-Src (Y416) and p-Src (Y527) were performed
(Additional file 1). According to the immunohistochemical
intrinsic subtypes, the KPL-1 and KPL-3C cell lines were
categorized as the luminal A subtype, the BT-474 cell line
as the luminal B subtype, the KPL-4 cell line as the HER2-
positive/ER-negative subtype, and the MDA-MB-231, MD-
MB-157 and HCC1937 cell lines as the basal-like subtype
[3]. HER1 overexpression was observed in cell lines of the
basal-like subtype. No detectable expression of BRCA1 was
observed in cell lines of the basal-like subtype. An active
form of c-Src, p-Src (Y416) was overexpressed in cell lines
of the basal-like subtype. Overexpression of vimentin was
observed in the MDA-MB-231 and MD-MB-157 cell lines
but not in the HCC1937 cell lines. According to these find-
ings and others’, the MDA-MB-231 and MD-MB-157 cell
lines are sub-categorized as the basal B subtype, and the
HCC1937 is as the basal A subtype [19].
Effects of dasatinib on Src phosphorylation
To clarify anti-Src activity of dasatinib on breast cancer
cells, changes in expression levels of c-Src and p-Src
(Y416 and Y527) were examined before and after the
treatment with dasatinib (0.1 or 1.0 μM) for 24 hours.
Although dasatinib did not significantly change the
expression levels of c-Src in any of the cell lines, dasati-
nib significantly suppressed the expression levels of
either p-Src (Y416) or p-Src (Y527) in all cell lines in a
dose-dependent manner (Figures 1, 2 and 3).
Antitumor activity of dasatinib and/or chemotherapeutic
agents
The IC50 for dasatinib was much lower than the
reported trough concentration of dasatinib in humans
(0.6 μM) in the MDA-MB-231 and MDA-MB-157 cell
lines (0.15 μM and 0.10 μM, respectively) [6]. In con-
trast, that for dasatinib was equal or over than 5.0 μM
in the other cell lines tested (Additional file 2).
The IC50s for Eto, Dox, Pac, Cis and SN38 were low-
est in the cell lines of basal B subtype but not those for
5-FU and Carb among the cell lines tested (Additional
file 2). The IC50s of chemotherapeutic agents were not
substantially different among the cell lines compared
with dasatinib.
Figure 1 Effects of dasatinib on c-Src phosphorylation in MDA-
MB-231 cells. Breast cancer cells were treated with indicated
concentrations of dasatinib for 24 hours. The expression levels of c-
Src, p-Src (Y416) and p-Src (Y527) were measured by the
immunocytochemical analysis described in the Materials and
Methods. Dasatinib dose-dependently decreased the expression
levels of p-Src (Y416 and Y-527) but not that of c-Src.
Kurebayashi et al. BMC Cancer 2010, 10:568
http://www.biomedcentral.com/1471-2407/10/568
Page 3 of 10To explore combined antitumor effects of dasatinib with
cytotoxic agents, combined treatments of dasatinib (0.1
μM) with the indicated concentrations of Eto were exam-
ined in the basal B cell lines. The combination index of the
IC50 was 0.2 in either cell line, that is, dasatinib additively
enhanced the antitumor effect of Eto in these cell lines
(Figures 4 and 5). Similar additive interactions were also
observed in the combination of dasatinib with Pac or SN38
in these cell lines (Supplementary Figure 2). These additive
interactions were not observed in the other cell lines.
To further clarify the combined antitumor effects of
dasatinib and Eto, combined treatments with Eto (0.1
μM) with the indicated concentrations of dasatinib were
examined in the basal B cell lines. The combination
index of IC50 was 0.3 or 0.4 in the MDA-MB-231 or
MDA-MB-157 cell line, respectively, that is, Eto addi-
tively enhanced the antitumor effect of dasatinib in
these cell lines (Figures 6 and 7).
Effects of dasatinib and Eto on cell cycle progression and
induction of apoptosis
To elucidate the mechanism of action of dasatinib and/
or Eto in the cell lines of the basal B subtype, effects of
single or combined treatments on cell cycle progression
and induction of apoptosis were examined. Dasatinib
(0.1 μM) induced a significant G1-S cell cycle blockade
associated with a slight apoptosis in both cell lines (Fig-
ures 8 and 9). Percentages of cells in the G0/G1 phase
Figure 2 Effects of dasatinib on c-Src phosphorylation in MDA-
MB-157 cells. Dasatinib dose-dependently decreased the
expression levels of p-Src (Y416 and Y-527) but not that of c-Src.
Figure 3 Effects of dasatinib on c-Src phosphorylation in BT-
474 cells. Dasatinib dose-dependently decreased the expression
levels of p-Src (Y416 and Y-527) but not that of c-Src.
Figure 4 Additive antitumor activity of dasatinib and Eto in
MDA-MB-231 cells. The cells were treated with indicated
concentrations of Eto and/or 0.1 μM dasatinib for three days, and
the cell count was measured by a Coulter counter as described in
the Materials and Methods. Dasatinib additively inhibited the
growth of MDA-MB-231 cells. Open circles represent values treated
with Eto alone. Closed circles represent values treated with Eto plus
dasatinib. The values are expressed as mean ± S.E. of at least two
separate experiments.
Figure 5 Additive antitumor activity of dasatinib and Eto in
MDA-MB-157 cells. The cells were treated with indicated
concentrations of Eto and/or 0.1 μM dasatinib for three days.
Dasatinib additively inhibited the growth of MDA-MB-157 cells.
Open circles represent values treated with Eto alone. Closed circles
represent values treated with Eto plus dasatinib. The values are
expressed as mean ± S.E. of at least two separate experiments.
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nib (P < 0.01) in MDA-MB-231 cells. Those were 60.5 ±
0.3 for the control and 70.8 ± 1.4 for dasatinib (P <
0.01) in MDA-MB-157 cells. Percentages of apoptotic
cells were 3.2 ± 0.2 for the control and 8.0 ± 0.1 for
dasatinib (P < 0.01) in MDA-MB-231 cells. These were
3.0 ± 0.5 for the control and 6.3 ± 0.5 for dasatinib (P <
0.01) in MDA-MB-157 cells. Eto (0.1 μM) induced a sig-
nificant G2 accumulation in the MDA-MB-231 cell line
(Figure 8). Percentages of cells in the G2/M phase were
18.8 ± 0.4 for the control and 25.4 ± 2.2 for Eto (P =
0.01) in MDA-MB-231 cells. Eto induced slight apopto-
sis in MDA-MB-157 cell lines (Figure 9). Percentages of
apoptotic cells were 3.0 ± 0.5 for the control and 6.0 ±
0.6 for Eto (P = 0.01) in MDA-MB-157 cells.
A combined treatment with dasatinib (0.1 μM) and
Eto (0.1 μM) induced a G1-S cell cycle blockade with or
without a slight apoptosis in both cell lines (Figure 8
and 9). Percentages of cells in the G0/G1 phase were
69.6 ± 0.9 for combined treatment (P < 0.01 compared
with the control) in MDA-MB-231 cells and 66.5 ± 0.7
Figure 6 Additive antitumor activity of dasatinib and Eto in
MDA-MB-231 cells. The cells were treated with indicated
concentrations of dasatinib and/or 0.1 μM Eto for three days. Eto
additively inhibited the growth of MDA-MB-157 cells. Open circles
represent values treated with dasatinib alone. Closed circles
represent values treated with Eto plus dasatinib. The values are
expressed as mean ± S.E. of at least two separate experiments.
Figure 7 Additive antitumor activity of dasatinib and Eto in
MDA-MB-157 cells. The cells were treated with indicated
concentrations of dasatinib and/or 0.1 μM Eto for three days. Eto
additively inhibited the growth of MDA-MB-157 cells. Open circles
represent values treated with dasatinib alone. Closed circles
represent values treated with Eto plus dasatinib. The values are
expressed as mean ± S.E. of at least two separate experiments.
Figure 8 Effects of dasatinib and Eto on cell cycle progression
and induction of apoptosis in MDA-MB-231 cells. The cells were
treated with 0.1 μM Eto and/or 0.1 μM dasatinib for two days, and
cell cycle and apoptosis were measured as described in the
Materials and Methods. Dasatinib induced a G1-S blockade with a
slight apoptosis, Eto induced a G2-M accumulation, and the
combined treatment induced a G1-S blockade with a slight
apoptosis in MDA-MB-231 cells.
Figure 9 Effects of dasatinib and Eto on cell cycle progression
and induction of apoptosis in MDA-MB-157 cells. Dasatinib
induced a G1-S blockade with a slight apoptosis, Eto induced a
slight G1-S blockade, and the combined treatment induced a G1-S
blockade with a slight apoptosis in MDA-MB-157 cells.
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control) in MDA-MB-157 cells. It should be noted that
Eto did not show any additive effect to the treatment
with dasatinib alone on G1-S cell cycle retardation and
increased apoptosis in both cell lines. These findings
suggest that the additive antitumor effect with dasatinib
and Eto is unlikely to be due to enhanced cell cycle
retardation or increased apoptosis in these cell lines.
Effects of dasatinib and/or Eto on the proportion of
ALDH1-positive cells
To test a hypothesis that dasatinib may more effectively
kill breast cancer stem cells than chemotherapeutic
agents, effects of dasatinib and/or Eto on the proportion
of ALDH1-positive cells in a panel of breast cancer cell
lines were examined using an immunocytochemical ana-
lysis and Aldefluor assay. The proportion of ALDH1-
positive cells was higher than that by the Aldefluor assay
but was in line with the results of the immunocytochem-
ical assay. Base-line proportions of ALDH1-positive cells
were higher in HER2-overexpressing BT-474 and KPL-4
cell lines than HER2-negative cell lines. Those of the
cell lines of the luminal A subtype were less than 1%
(Additional file 3).
Dasatinib treatment (0.1 or 1.0 μM) significantly
decreased the proportion of ALDH1-positive cells in the
cell lines of the basal B subtype (Figures 10 and 11). In
contrast, it increased the proportion in the BT-474 cell
line (Figure 12). Eto treatment (0.1 or 1.0 μM) did not
significantly decrease the proportion of ALDH1-positive
cells in any of the cell lines tested. A combined
treatment of dasatinib with Eto also significantly
decreased the proportion of ALDH1-positive cells in the
cell lines of the basal B subtype (Figures 10 and 11).
The proportion of ALDH1-positive cells was 13.0 ±
1.4% for the control, 7.0 ± 1.6% for 0.1 μMd a s a t i n i b ,
11.7 ± 0.1% for 0.1 μM Eto, and 5.2 ± 1.6% for
Figure 10 Effects of dasatinib and/or Eto on the proportion of
ALDH1-positive cells in MDA-MB-231 cells. The cells were
treated with 0.1 μM Eto and/or 0.1 μM dasatinib for two days, and
ALDH1-positive cells were measured by the immunocytochemical
analysis as described in the Materials and Methods. Dasatinib alone
and dasatinib with Eto significantly decreased the proportion of
ALDH1-positive cells in MDA-MB-231 cells. *P < 0.05.
Figure 11 Effects of dasatinib and/or Eto on the proportion of
ALDH1-positive cells in MDA-MB-157 cells. The cells were
treated with 0.1 μM Eto and/or 0.1 μM dasatinib for two days, and
ALDH1-positive cells were measured by the immunocytochemical
analysis as described in the Materials and Methods. Dasatinib alone
and dasatinib with Eto significantly decreased the proportion of
ALDH1-positive cells in MDA-MB-157 cells. **P < 0.01.
Figure 12 Effects of dasatinib and/or Eto on the proportion of
ALDH1-positive cells in BT-474 cells. The cells were treated with
0.1 μM Eto and/or 0.1 μM dasatinib for two days, and ALDH1-
positive cells were measured by the immunocytochemical analysis
as described in the Materials and Methods. Dasatinib slightly
increased the proportion of ALDH1-positive cells in BT-474 cells.
*P < 0.05.
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ences were significant among the control vs. dasatinib
alone (P = 0.03) and Eto alone vs. combined treatment
(P = 0.03). The proportion of ALDH1-positive cells was
14.1 ± 1.8% for the control, 7.3 ± 0.5% for 0.1 μMd a s a -
tinib, 15.6 ± 1.8% for 0.1 μM Eto, and 4.5 ± 1.9% for
combined treatment in MDA-MB-157 cells. The differ-
ences were significant among the control vs. dasatinib
alone (P = 0.01) and Eto alone vs. combined treatment
(P < 0.01). No difference was observed between dasati-
nib alone and combined treatment in either cell line.
These findings suggest that Eto did not enhance the
decreased proportion of ALDH1-positive cells by dasati-
nib alone in these cell lines.
Representative results demonstrated by the immuno-
cytochemistry and Aldefluor assays are shown in Figures
13, 14 and 15.
Discussion
To develop novel treatment strategies against triple
negative/basal-like breast cancer, molecular targeting
agents such as inhibitors of Src, poly(ADP-ribose) poly-
merase (PARP) 1, HER1 or the vascular endothelial
growth factor (VEGF) signaling pathway have been
tested in preclinical and clinical studies [4]. Dasatinib is
an orally active small molecule inhibitor of both the Src
and Abl, and was approved for the treatment of imatinib
refractory chronic myelogenous leukemia and bcr-abl
positive acute lymphoblastic leukemia [20]. Additionally,
recent preclinical studies have indicated significant anti-
tumor activity of dasatinib in breast cancer cells of the
basal-like/triple negative subtype in vitro [5,6]. Other
preclinical studies have also supported the role of Src
inhibition with dasatinib in head and neck cancer, pan-
creatic cancer, lung cancer and osteosarcoma models
[21-24]. Very recently, a preliminary study has shown
that dasatinib monotherapy shows substantial antitumor
activity in heavily-pretreated patients with triple negative
metastatic breast cancer [25].
To further clarify the potential clinical role of the Src
inhibitor dasatinib in breast cancer, we examined the
in vitro effects of dasatinib using a panel of human
breast cancer cell lines of four different subtypes
(Additional file 1). Results of the present study have
demonstrated that dasatinib effectively inhibited phos-
phorylation of c-Src in all cell lines tested (Figures 1, 2
and 3), and preferentially inhibited the growth of
breast cancer cells of the basal B subtype (Additional
file 2). The IC50s of dasatinib in the basal B breast
cancer cell lines were approximately 4-6 times lower
than the trough concentration (0.6 μM) of dasatinib in
humans [6]. These findings coincide with those
reported by two independent groups [5,6].
To test a hypothesis that dasatinib may enhance anti-
tumor activity of chemotherapeutic agents, we first
examined the growth inhibitory effects of seven anti-
cancer agents commonly used for the treatment of
breast cancer. According to the IC50 for each agent,
breast cancer cells of the basal B subtype seemed to be
more sensitive to DNA-damaging agents such as Eto,
Dox, Cis, Carb and SN38 than those of other subtypes,
in particular, the luminal A and luminal B subtypes
(Additional file 2). These findings may be partly
explained by the facts that a loss of BRCA1 expression
is frequently observed in breast cancer cells of the basal
B subtype, and BRCA1 dysfunction enhances antitumor
activity of DNA-damaging agents in breast cancer cells.
Actually, BRCA1 expression levels measured by the
immunocytochemical assay were significantly lower
in three basal-like breast cancer cell lines (Additional
file 1).
One of the DNA-damaging agents, Eto has long been
used in the treatment of various malignancies such as
lung cancer [26]. Recent clinical studies have also
demonstrated that oral Eto in combination with intra-
venous Cis has a significant antitumor effect on meta-
static breast cancer [27]. Since both dasatinib and Eto
can be administered orally, breast cancer patients
could be treated with these agents without intravenous
injections. These findings prompted us to investigate
a combined antitumor activity of dasatinib with Eto
in breast cancer cells of the basal B subtype. Dasatinib
(0.1 μM) additively enhanced antitumor activity
(Figures 4, 5, 6 and 7).
To elucidate the mechanism of action of combined
treatment with dasatinib and Eto, the effects of single or
combined treatments on cell cycle progression and
Figure 13 Effects of dasatinib on the proportion of ALDH1-
positive cells in breast cancer cells. The immunocytochemical
analyses demonstrated a decrease in the proportion of ALDH1-
positive cells by dasatinib in MDA-MB-231 and MDA-MB-157 cells
but an increase in the proportion of ALDH1-positive cells by
dasatinib in BT-474 cells.
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Eto did not show any additive effect to the treatment
with dasatinib alone on G1-S cell cycle retardation and
increased apoptosis (Figures 8 and 9). In addition, the
immunocytochemical and Aldefluor assay showed that
Eto did not enhance the decreased proportion of
ALDH1-positive cells by dasatinib alone (Figures 10, 11,
12, 13, 14 and 15). These findings suggest that the addi-
tive antitumor effect with dasatinib and Eto is unlikely
to be due to enhanced cell cycle retardation, increased
apoptosis or decreased proportion of ALDH1-positive,
putative cancer stem cells. Further studies are needed to
elucidate the mechanism of action responsible for possi-
ble additive antitumor activity with dasatinib and a che-
motherapeutic agent. Otherwise, similar additive
antitumor interactions were observed in the combina-
tions of dasatinib with Pac and SN38 (Additional files 4,
5, 6 and 7). Combined administrations of dasatinib with
Figure 14 Effects of dasatinib and/or Eto on the proportion of ALDH1-positive cells in breast cancer cells. The Aldefluor assay
demonstrated that dasatinib alone and dasatinib with Eto decreased the proportion of ALDH1-positive cells in MDA-MB-231 cells.
Figure 15 Effects of dasatinib and/or Eto on the proportion of ALDH1-positive cells in breast cancer cells. The Aldefluor assay
demonstrated that dasatinib alone and dasatinib with Eto increased the proportion of ALDH1-positive cells in BT-474 cells.
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treatment of breast cancers of the basal B subtype.
Recent preclinical studies have suggested that a small
component of tumor cells, so-called cancer stem cells play
critical roles in the development, progression, metastasis
and resistance to chemotherapy and radiotherapy in
malignancies [28]. Interestingly, it was reported that a dual
HER1/HER2 inhibitor lapatinib significantly reduced the
proportion of CD44+/CD24- breast cancer cells, putative
stem cells, and also reduced the number of mammo-
sphere-forming activity associated with a significant anti-
tumor activity in HER2-positive breast cancers in
the neoadjuvant setting [13]. In contrast, cytotoxic che-
motherapies including Dox increased the proportion of
CD44/CD24- breast cancer cells and mammosphere-
forming activity associated with a significant antitumor
activity in HER2-negative breast cancers [13]. Notably, a
very recent study has shown that cytotoxic chemothera-
pies including an anthracycline and taxane increased the
proportion of ALDH1-positive breast cancer cells but not
that of CD44+/CD24- breast cancer cells [29]. Addition-
ally, another preclinical study has suggested that anti-
HER2 monoclonal antibody trastuzumab effectively
decreases the proportion of putative breast cancer stem
cells in HER2-positive breast cancer cells [12]. More
recently, an anti-diabetes mellitus agent metformin and
8-quinolinol have been reported to effectively target breast
cancer stem cells and synergistically inhibit tumor growth
together with the chemotherapeutic agents Dox and Pac,
respectively [30]. These emerging preclinical data suggest
that a combined use of anti-stem cell agents with che-
motherapeutic agents might provide a longer tumor
regression as well as cure for patients with malignancies.
To investigate the effects of dasatinib and Eto on breast
cancer stem cells, the proportion of ALDH1-positive cells
was examined before and after the treatments with these
agents using immunocytochemistry and Aldefluor assay.
Interestingly, dasatinib significantly decreased the propor-
tion of ALDH1-positive cells in breast cancer cell lines of
the basal B subtype, which were highly sensitive to dasati-
nib. In contrast, dasatinib significantly increased the pro-
portion of ALDH1-positive cells in the BT-474 cell line,
which was categorized as the luminal B subtype and insen-
sitive to dasatinib. A cytotoxic agent Eto did not signifi-
cantly decrease the proportion of ALDH1-positive cells in
breast cancer cell lines of either luminal B or basal B
subtypes (Figures 10, 11 and 12). These findings strongly
suggest for the first time that the Src inhibitor dasatinib
preferentially decreased the proportion of ALDH1-
positive, putative breast cancer stem cells in breast cancer
cells of the basal B subtype. However, mechanisms of
action responsible for the anti-stem cell activity of dasati-
nib still remain to be elucidated. A recent preclinical study
indicated that ablation of focal adhesion kinase (FAK)
reduces the proportion of cancer stem cells in either an
in vitro or in vivo model [31]. Because FAK is known to
interact with the Src family members and its activation is
reported to be suppressed by dasatinib, the inhibitory effect
of dasatinib on the FAK signaling pathway might explain
the anti-stem cell activity of dasatinib. Further studies are
clearly needed to elucidate the mechanism of action of
dasatinib responsible for its anti-stem cell activity.
Conclusions
T ot h eb e s to fo u rk n o w l e d g e ,t h ep r e s e n ts t u d yh a s
offered clear evidence that the Src inhibitor dasatinib
preferentially inhibited the growth of breast cancer cells
of the basal B subtype associated with a G1-S cell cycle
blockade and a reduction in the proportion of ALDH1-
positive, putative breast cancer stem cells. In addition,
dasatinib significantly enhanced an anti-tumor activity
of one of DNA-damaging agents Eto in breast cancer
cells of the basal B subtype. These strong preclinical
findings warrant clinical trials using dasatinib and Eto in
patients with breast cancer of the basal B subtype.
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